Book online
Choose the service you need and complete a short intake. No referral is needed.
TelePlus Care
Mounjaro Online Prescription in Alberta
Access Mounjaro (tirzepatide), the groundbreaking dual-action medication for weight loss and Type 2 diabetes, through a convenient virtual consultation with TelePlus Care. Our Canadian licensed doctors can evaluate your eligibility and prescribe Mounjaro from the comfort of your home. Mounjaro represents the newest class of weight management medications, targeting both GIP and GLP-1 receptors for enhanced results compared to single-action therapies.
Book Weight-Loss AssessmentCovered with a referral + Alberta Health Card · $149 private · shown before payment
⏱️Private Virtual Visit
👨⚕️Licensed Canadian Doctors
🔒PIPEDA Secure & Private
✓Trusted by 500+ Patients
Quick Answer
Mounjaro (tirzepatide) is the first dual GIP/GLP-1 receptor agonist approved by Health Canada for Type 2 diabetes, producing average weight loss of 22.5% on the 15 mg dose in SURMOUNT-1 clinical trials. TelePlus Care offers virtual tirzepatide consultations across Alberta, with licensed doctors evaluating eligibility, managing dose escalation, and prescribing through secure telemedicine.
- Dual GIP/GLP-1 mechanism — only one of its kind in Canada
- Up to 22.5% body weight reduction at 15 mg over 72 weeks
- HbA1c reduction of 2.0-2.6 percentage points (highest among GLP-1s)
- Same-week appointments — fill your prescription at any Alberta pharmacy
Medically reviewed by Dr. Maher Jerudi, MD
Last reviewed:
Clinical content is reviewed for accuracy and scope. TelePlus Care appointments go ahead only when a doctor agrees it is the right call, after a real assessment, and the doctor will explain the next step if virtual care is not the right fit.
What Is Mounjaro?
Mounjaro is a brand-name prescription medication containing tirzepatide, manufactured by Eli Lilly. It is the first and only dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by Health Canada. Originally developed for the treatment of Type 2 diabetes, Mounjaro has demonstrated remarkable weight loss results in clinical trials, making it one of the most sought-after medications for both blood sugar management and weight reduction. Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled, single-dose pen.
How Does Tirzepatide Work? The Dual GIP/GLP-1 Mechanism
What sets Mounjaro apart from other weight loss and diabetes medications is its unique dual-action mechanism. Unlike single-action GLP-1 receptor agonists such as Ozempic or Wegovy, tirzepatide simultaneously activates both GIP and GLP-1 receptors, producing complementary metabolic effects that may lead to superior outcomes.
- GLP-1 receptor activation -- Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through brain signalling pathways. These are the same mechanisms used by semaglutide (Ozempic/Wegovy).
- GIP receptor activation -- Enhances insulin sensitivity, improves fat metabolism, and may increase energy expenditure. GIP signalling also appears to amplify the appetite-suppressing effects of GLP-1.
- Synergistic appetite suppression -- The combined activation of both receptors produces a more powerful reduction in hunger and food cravings than either pathway alone.
- Enhanced insulin sensitivity -- Tirzepatide improves how your body responds to insulin, helping to lower blood sugar more effectively and reduce insulin resistance.
- Improved lipid metabolism -- The dual mechanism helps reduce triglycerides and improve cholesterol profiles, providing additional cardiovascular benefits.
- Greater calorie deficit -- By reducing appetite and potentially increasing metabolic rate through GIP activation, Mounjaro may create a larger calorie deficit than single-action medications.
Mounjaro Weight Loss Results
Mounjaro has produced some of the most impressive weight loss results of any pharmaceutical intervention in clinical history. The SURMOUNT series of clinical trials demonstrated that tirzepatide can help patients achieve weight loss outcomes previously only seen with bariatric surgery.
- SURMOUNT-1 trial -- Participants without diabetes lost an average of 22.5% of their body weight on the highest dose (15 mg) over 72 weeks. That is approximately 52 pounds for someone starting at 230 pounds.
- SURMOUNT-2 trial -- Participants with Type 2 diabetes lost an average of 14.7% of their body weight on the 15 mg dose over 72 weeks.
- Superior to semaglutide -- Head-to-head comparisons in clinical trials have shown that tirzepatide produces greater weight loss than semaglutide (Ozempic) at comparable treatment durations.
- Waist circumference reduction -- Patients experienced significant reductions in waist circumference, indicating loss of harmful visceral fat around internal organs.
- Sustained results -- Weight loss continued throughout the treatment period, with many patients still losing weight at the end of the 72-week trials.
- Metabolic improvements -- Beyond weight loss, patients experienced improvements in blood pressure, cholesterol, triglycerides, and inflammatory markers.
Mounjaro for Type 2 Diabetes
Mounjaro is approved by Health Canada for the treatment of Type 2 diabetes in adults as an adjunct to diet and exercise. Clinical trials have demonstrated that tirzepatide provides superior blood sugar control compared to many existing diabetes treatments.
- HbA1c reduction -- Mounjaro can lower HbA1c by 2.0–2.6 percentage points at the highest dose, surpassing the efficacy of most other diabetes medications.
- Fasting glucose improvement -- Significant reductions in fasting blood glucose levels have been observed across all doses of tirzepatide.
- Greater insulin sensitivity -- The dual GIP/GLP-1 mechanism improves insulin sensitivity more effectively than single-action GLP-1 agonists.
- Reduced need for additional medications -- Many patients on Mounjaro are able to reduce or eliminate other diabetes medications under their doctor's guidance.
- Weight loss benefit -- Unlike sulfonylureas and insulin, which often cause weight gain, Mounjaro promotes substantial weight loss, further improving metabolic health.
- Cardiovascular risk reduction -- Emerging data suggests tirzepatide may reduce the risk of major adverse cardiovascular events in patients with Type 2 diabetes.
Mounjaro Dosage Guide
Mounjaro follows a structured dose-escalation schedule designed to minimize side effects and allow your body to adapt gradually. Your TelePlus Care doctor will guide you through each dose adjustment based on your tolerance and clinical response.
- Weeks 1–4: 2.5 mg once weekly -- The starting dose is designed for tolerability, not therapeutic effect. Most patients experience minimal side effects at this level.
- Weeks 5–8: 5 mg once weekly -- The first therapeutic dose. Many patients begin to see meaningful reductions in blood sugar and early appetite changes.
- Weeks 9–12: 7.5 mg once weekly -- An intermediate dose for patients who need additional efficacy beyond 5 mg but are not yet ready for higher doses.
- Weeks 13–16: 10 mg once weekly -- A commonly used maintenance dose that provides significant blood sugar control and weight loss.
- Weeks 17–20: 12.5 mg once weekly -- An intermediate step for patients being escalated to the maximum dose.
- Week 21 and beyond: 15 mg once weekly -- The maximum dose, providing the greatest reductions in HbA1c and body weight. Not all patients require this dose.
- Important: Dose adjustments should only be made under the guidance of your TelePlus Care doctor based on your individual response and tolerance.
Side Effects of Mounjaro
The side effect profile of Mounjaro is similar to that of other GLP-1 receptor agonists. Most side effects are gastrointestinal and tend to occur during dose escalation, improving as your body adjusts. Starting at a low dose and increasing gradually helps minimize these effects.
- Nausea -- The most frequently reported side effect, typically mild and decreasing over time. Affecting approximately 12–18% of patients.
- Diarrhea -- Loose or more frequent stools may occur, particularly during the first few weeks of each dose increase.
- Decreased appetite -- A desired effect for weight loss, though some patients may find the reduction in appetite more pronounced than expected.
- Vomiting -- Some patients experience vomiting, most commonly during initial weeks or after dose escalation.
- Constipation -- Slowed gastric emptying may lead to constipation in certain individuals.
- Abdominal pain -- Mild to moderate stomach discomfort may occur.
- Injection site reactions -- Redness, itching, or minor swelling at the injection site are occasionally reported.
- Rare but serious: pancreatitis -- Contact your doctor immediately if you experience severe, persistent abdominal pain radiating to the back.
- Rare but serious: hypoglycemia -- Low blood sugar is uncommon when Mounjaro is used alone but may occur when combined with insulin or sulfonylureas.
Who Qualifies for Mounjaro?
During your virtual consultation, your TelePlus Care doctor will assess your medical history, current health status, and treatment goals to determine whether Mounjaro is an appropriate option for you.
- Type 2 diabetes diagnosis -- Mounjaro is approved for adults with Type 2 diabetes as an adjunct to diet and exercise to improve glycemic control.
- BMI of 30 or higher -- Physicians may prescribe Mounjaro off-label for weight management in individuals classified as obese.
- BMI of 27 or higher with comorbidities -- Overweight individuals with conditions such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease may qualify.
- Inadequate response to other treatments -- Patients who have not achieved sufficient blood sugar control or weight loss with other medications may benefit from Mounjaro.
- No history of medullary thyroid cancer -- Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
- No history of severe gastrointestinal disease -- Patients with gastroparesis or severe inflammatory bowel disease should discuss alternatives with their doctor.
- Not pregnant or planning pregnancy -- Mounjaro should be discontinued at least two months before a planned pregnancy.
How to Get Mounjaro Online at TelePlus Care
Our streamlined virtual care process makes it easy to access Mounjaro without visiting a clinic in person. TelePlus Care connects you with licensed doctors who specialize in weight management and diabetes care.
- Step 1: Book your virtual consultation -- Use our online booking system to see current appointment times; same-day or next-day options may be available.
- Step 2: Complete your health intake -- Before your appointment, fill out a comprehensive medical questionnaire covering your health history, medications, and goals.
- Step 3: Consult with your doctor -- Meet with a licensed doctor via secure video or phone call. Your doctor will evaluate whether Mounjaro is appropriate for your needs.
- Step 4: Prescription and pharmacy -- If prescribed, your Mounjaro prescription will be issued for you to fill at your preferred Alberta pharmacy for pickup or delivery.
- Step 5: Follow-up care -- Schedule regular follow-up appointments to monitor progress, manage side effects, and adjust your dosage. Your doctor will be available for ongoing guidance.
Access to Mounjaro in Alberta
A licensed doctor reviews your intake before the visit and explains the safest next step.
Mounjaro vs Ozempic: Key Differences
Both Mounjaro and Ozempic are effective GLP-1-based medications, but they differ in important ways. Understanding these differences can help you and your doctor choose the best option for your individual needs.
- Mechanism of action -- Mounjaro targets both GIP and GLP-1 receptors (dual agonist), while Ozempic targets only GLP-1 receptors (single agonist).
- Weight loss -- Clinical trials show Mounjaro produces approximately 5–7% greater body weight reduction than Ozempic at comparable treatment durations.
- HbA1c reduction -- Mounjaro has demonstrated slightly greater HbA1c reductions (2.0–2.6%) compared to Ozempic (1.0–1.8%).
- Dosing range -- Mounjaro is available in six dose strengths (2.5 mg to 15 mg), while Ozempic offers four (0.25 mg to 2 mg).
- Approval status -- Both are approved for Type 2 diabetes. Weight loss approval varies by jurisdiction and continues to evolve.
- Access note: Mounjaro availability varies by location, dose strength, and pharmacy supply.
- Side effects -- Both medications have similar gastrointestinal side effect profiles, though individual tolerance varies.
Mounjaro Online Prescription in Alberta — Fast, Convenient Virtual Care
Book online with Dr. Jerudi. Covered by Alberta Health with a referral from your family doctor or nurse practitioner, or book directly as a $149 private visit.
Book Weight-Loss AssessmentExplore Our Alberta Services
TelePlus Care is not an urgent care clinic. If you have an emergency, please call 911 or go to the nearest urgent care facility.
Alberta
Virtual care in Alberta: coverage & licensing
TelePlus Care offers adults in Alberta and surrounding communities an online medical weight-loss assessment by secure phone or video. With an active Alberta Health Card and a referral from your family doctor or nurse practitioner, the visits are covered by Alberta Health; without a referral the initial assessment is a $149 private visit. Medication and pharmacy costs are separate.
Licensed in Alberta
You are seen by a Canadian licensed doctor authorized by the College of Physicians and Surgeons of Alberta (CPSA) to care for patients in Alberta.
Public insurer: AHCIP
Health care in Alberta is administered through Alberta Health Care Insurance Plan. Weight Loss Online visits are covered by Alberta Health with an active Alberta Health Card and a referral from your family doctor or nurse practitioner. Without a referral, the initial assessment is a $149 private visit. Medication, laboratory, and pharmacy costs are separate when recommended.
Free health advice
For free, publicly funded non-urgent health advice in Alberta, you can also call Health Link (811).
Emergencies: call 911
Online care is not for emergencies. For severe or rapidly worsening symptoms, call 911 or go to your nearest emergency department.
What to expect from a TelePlus Care virtual visit in Alberta
Meet a doctor
Speak with a Canadian licensed doctor by phone or secure video, daily from 8:00 AM to 7:00 PM Mountain Time.
Leave with a plan
When clinically appropriate, you can receive a prescription, a note, a lab requisition, or a referral.
Know when to go in person
Virtual care is not for emergencies. Call 911 for an emergency, or 811 for free nurse advice.
Want to hear from patients? Read TelePlus Care reviews on Google
